Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

06 Jan 2023 18:00 CET

Regulatory News:

Under the liquidity agreement entrusted by IPSEN to NATIXIS ODDO BHF, as of December 31, 2022, the following resources were included to the dedicated liquidity account:

• 24,069 shares
• €2,483,094.99

It is reminded that as of the date of the implementation of the agreement, the following resources were allocated to the liquidity account:

• 12,751 shares
• €3,137,934.80

Between July 1^st, 2022 and December 31^st, 2022 have been executed:

• 2,466 purchase transactions
• 2,235 sell transactions

Under the same period, the volumes traded represented:

• 296,190 shares and €29,245,027.80 to the purchase
• 299,127 shares and €29,692,331.70 to the sell

Ipsen
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230106005009/en/

Investors
Craig Marks
Vice President, Investor Relations
+44 (0)7584 349 193

Adrien Dupin de Saint-Cyr
Investor Relations Manager
+33 6 64 26 17 49

Media
Amy Wolf
Vice President and Head of Corporate Brand Strategy
and Communications
+41 79 576 07 23

Ioana Piscociu
Senior Manager,
Global Media Relations
+ 33 6 69 09 12 96